UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

Science (American Association for the Advancement of Science), 2017-08, Vol.357 (6350), p.507-511

2017

Volltextzugriff (PDF)

Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts

Diabetes (New York, N.Y.), 2018-06, Vol.67 (6), p.1173-1181

2018

Volltextzugriff (PDF)

Fat Intake Affects Adiposity, Comorbidity Factors, and Energy Metabolism of Sprague-Dawley Rats

Obesity (Silver Spring, Md.), 2002-09, Vol.10 (9), p.956-963

2002

Volltextzugriff (PDF)

Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors

Bioorganic & medicinal chemistry letters, 2014-04, Vol.24 (7), p.1790-1794

2014

Volltextzugriff (PDF)

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

British journal of pharmacology, 2001-09, Vol.134 (2), p.409-417

2001

Volltextzugriff (PDF)

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

British journal of pharmacology, 2000-04, Vol.129 (8), p.1748-1754

2000

Volltextzugriff (PDF)

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

European journal of pharmacology, 2001-03, Vol.415 (1), p.79-84

2001

Volltextzugriff (PDF)

SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist

Bioorganic & medicinal chemistry letters, 2012-01, Vol.22 (2), p.854-858

2012

Volltextzugriff (PDF)

Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia

ACS medicinal chemistry letters, 2012-01, Vol.3 (1), p.63-68

2012

Volltextzugriff (PDF)

Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters

Diabetes (New York, N.Y.), 2001-06, Vol.50 (6), p.1330-1335

2001

Volltextzugriff (PDF)

Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats

British journal of pharmacology, 2003-04, Vol.138 (8), p.1459-1464

2003

Volltextzugriff (PDF)

Engineering Glucose Responsiveness Into Insulin

Diabetes (New York, N.Y.), 2018-02, Vol.67 (2), p.299-308

2018

Volltextzugriff (PDF)

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

European journal of pharmacology, 2008-04, Vol.584 (1), p.118-124

2008

Volltextzugriff (PDF)

Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys

American journal of physiology: endocrinology and metabolism, 2017-04, Vol.312 (4), p.E235-E243

2017

Volltextzugriff (PDF)

Erratum. Engineering Glucose Responsiveness Into Insulin. Diabetes 2018;67:299-308

Diabetes (New York, N.Y.), 2018-05, Vol.67 (5), p.1030-1030

2018

Volltextzugriff (PDF)

Discovery of XEN445: A potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice

Bioorganic & medicinal chemistry, 2013-12, Vol.21 (24), p.7724-7734

2013

Volltextzugriff (PDF)

Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors

ACS medicinal chemistry letters, 2014-05, Vol.5 (5), p.544-549

2014

Volltextzugriff (PDF)

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

European journal of pharmacology, 2002-04, Vol.440 (2), p.173-187

2002

Volltextzugriff (PDF)

Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity

Bioorganic & medicinal chemistry letters, 2013-11, Vol.23 (21), p.6004-6009

2013

Volltextzugriff (PDF)

Discovery of phenyl acetamides as potent and selective GPR119 agonists

Bioorganic & medicinal chemistry letters, 2017-03, Vol.27 (5), p.1124-1128

2017

Volltextzugriff (PDF)

Identification of 2-aminooxazole amides as acyl-CoA: Diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy

Bioorganic & medicinal chemistry letters, 2013-12, Vol.23 (23), p.6410-6414

2013

Volltextzugriff (PDF)

Cholesteryl Hydroperoxyoctadecadienoate from Oxidized Low Density Lipoprotein Inactivates Platelet-derived Growth Factor

The Journal of biological chemistry, 1998-07, Vol.273 (31), p.19405-19410

1998

Volltextzugriff (PDF)

Diet-induced obese mice develop peripheral, but not central, resistance to leptin

The Journal of clinical investigation, 1997-02, Vol.99 (3), p.385-390

1997

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(42)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts

Pharmacological AMPK activation induces transcriptional responses congruent to exercise in skeletal and cardiac muscle, adipose tissues and liver

Fat Intake Affects Adiposity, Comorbidity Factors, and Energy Metabolism of Sprague-Dawley Rats

Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist

Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia

Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters

Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats

Engineering Glucose Responsiveness Into Insulin

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys

Erratum. Engineering Glucose Responsiveness Into Insulin. Diabetes 2018;67:299-308

Discovery of XEN445: A potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice

Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity

Discovery of phenyl acetamides as potent and selective GPR119 agonists

Identification of 2-aminooxazole amides as acyl-CoA: Diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy

Cholesteryl Hydroperoxyoctadecadienoate from Oxidized Low Density Lipoprotein Inactivates Platelet-derived Growth Factor

Diet-induced obese mice develop peripheral, but not central, resistance to leptin

Suchergebnisse filtern